PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-188.64%
Negative net income growth while VET stands at 72.15%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
No Data
No Data available this quarter, please select a different quarter.
11.84%
Some yoy growth while VET is negative at -690.89%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
-15.09%
Negative yoy SBC while VET is 24.59%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-53.33%
Negative yoy working capital usage while VET is 9.44%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
-342.86%
AR is negative yoy while VET is 0.00%. Joel Greenblatt would see a short-term cash advantage if revenue remains unaffected vs. competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-53.33%
Negative yoy usage while VET is 9.44%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-24.19%
Negative yoy while VET is 5366.29%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
6.99%
Operating cash flow growth 1.25-1.5x VET's 5.64%. Bruce Berkowitz might see better working capital management or consistent margin advantages.
-72.20%
Both yoy lines negative, with VET at -183.09%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
-99.23%
Negative yoy acquisition while VET stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
1080.00%
Purchases growth of 1080.00% while VET is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
72.20%
Liquidation growth of 72.20% while VET is zero at 0.00%. Bruce Berkowitz sees a mild difference in monetizing portfolio items that must be justified by market valuations.
-47.32%
We reduce yoy other investing while VET is 138.35%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
-129.52%
Both yoy lines negative, with VET at -107.86%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
98.87%
Debt repayment similar to VET's 97.20%. Walter Schloss sees parallel liability management or similar free cash flow availability.
-84.91%
Negative yoy issuance while VET is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.